- Home
- LUCD vs LTRN Comparison
LUCD vs LTRN Comparison
Compare LUCD & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- LTRN
- Stock Information
- Founded
- LUCD 2018
- LTRN 2013
- Country
- LUCD United States
- LTRN United States
- Employees
- LUCD N/A
- LTRN N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- LTRN Health Care
- Exchange
- LUCD Nasdaq
- LTRN Nasdaq
- Market Cap
- LUCD 38.4M
- LTRN 36.2M
- IPO Year
- LUCD 2021
- LTRN 2020
- Fundamental
- Price
- LUCD $0.98
- LTRN $3.13
- Analyst Decision
- LUCD Strong Buy
- LTRN Hold
- Analyst Count
- LUCD 4
- LTRN 1
- Target Price
- LUCD $3.69
- LTRN N/A
- AVG Volume (30 Days)
- LUCD 535.1K
- LTRN 56.9K
- Earning Date
- LUCD 11-13-2024
- LTRN 11-07-2024
- Dividend Yield
- LUCD N/A
- LTRN N/A
- EPS Growth
- LUCD N/A
- LTRN N/A
- EPS
- LUCD N/A
- LTRN N/A
- Revenue
- LUCD $4,189,000.00
- LTRN N/A
- Revenue This Year
- LUCD $88.47
- LTRN N/A
- Revenue Next Year
- LUCD $238.94
- LTRN N/A
- P/E Ratio
- LUCD N/A
- LTRN N/A
- Revenue Growth
- LUCD 179.27
- LTRN N/A
- 52 Week Low
- LUCD $0.63
- LTRN $2.79
- 52 Week High
- LUCD $1.58
- LTRN $11.99
- Technical
- Relative Strength Index (RSI)
- LUCD 54.35
- LTRN 43.16
- Support Level
- LUCD $0.90
- LTRN $2.79
- Resistance Level
- LUCD $1.12
- LTRN $3.57
- Average True Range (ATR)
- LUCD 0.07
- LTRN 0.27
- MACD
- LUCD -0.01
- LTRN -0.03
- Stochastic Oscillator
- LUCD 36.55
- LTRN 31.48
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.